Ophidian Paramyxovirus in Emerald Tree Boas

Ophidian Paramyxovirus (OPMV), now formally classified as ferlavirus within the genus Ferlavirus of the family Paramyxoviridae, is one of the longest-recognized viral pathogens of captive snakes. First described following a fatal outbreak in a Swiss serpentarium in 1972, it has since been documented in snake collections worldwide across all major snake families, including Boidae. For Corallus caninus and Corallus batesii keepers, ferlavirus is a relevant differential for any respiratory or neurological presentation and a reason to maintain rigorous quarantine and biosecurity practices.

This page is for informational purposes only and does not constitute veterinary advice. If you suspect your animal is unwell, contact a reptile-experienced veterinarian promptly.

What Ferlavirus Is

Ferlaviruses are enveloped, negative-sense single-stranded RNA viruses belonging to the order Mononegavirales. The same order includes measles virus, mumps virus, and Newcastle disease virus, reflecting a shared basic genome architecture across a wide range of vertebrate pathogens. Being enveloped viruses, ferlaviruses are less environmentally stable than non-enveloped viruses such as parvovirus or adenovirus, meaning standard disinfectants effective against enveloped viruses should be active against ferlavirus on contaminated surfaces.

The virus was first isolated from a common lancehead viper (Bothrops atrox) and initially named Fer-de-Lance virus (FDLV), a name still used in some literature alongside OPMV. The current accepted taxonomic name is ferlavirus. Four genogroups have been described: A, B, C, and a tortoise-associated group. These genogroups differ in pathogenicity, with genogroup B isolates associated with more severe disease in experimental infection studies than genogroup A or C strains. Concurrent infection with multiple genogroups within a single animal or collection has been documented.

Ferlavirus has been detected across all major snake families including Viperidae, Elapidae, Colubridae, Boidae, Crotalidae, and Pythonidae. While vipers have historically been the most severely affected group and the primary focus of early research, boids including boa constrictors have repeatedly tested positive in both clinical and surveillance contexts. The severity of disease varies by host species, virus strain, and individual immune status.

How the Virus Causes Disease

Following infection, ferlavirus spreads rapidly from the respiratory tract into multiple organ systems. Experimental infection studies in corn snakes demonstrated that virus was detectable in the lung within four days of intratracheal inoculation, and subsequently spread to the intestine, pancreas, kidney, and brain. This systemic distribution is what distinguishes ferlavirus clinically from a purely respiratory pathogen and explains why neurological signs can appear alongside or even in the absence of prominent respiratory disease.

In the lungs, ferlavirus triggers severe inflammation of the respiratory epithelium and surrounding interstitium. The resulting pneumonia can be exudative, with accumulation of inflammatory material and fluid impairing gas exchange, or proliferative, with abnormal thickening of airway tissue. The pancreas is a particularly notable secondary target, with pancreatitis and pancreatic necrosis documented at necropsy in affected animals. Hepatic involvement and nephritis have also been reported. In the brain, inflammation causes encephalitis that manifests as the neurological signs characteristic of advanced ferlavirus disease.

Secondary bacterial infections are common and frequently contribute to death. The severe airway inflammation created by the virus provides an environment where opportunistic gram-negative bacteria can establish themselves, and most affected snakes that die are found to have concurrent bacterial pneumonia. This means antibiotic treatment, while not targeting the virus itself, is a meaningful component of supportive care.

Disease severity is influenced by immune status. Geriatric animals and immunocompromised individuals appear more susceptible to severe disease. Stressed animals are also at elevated risk, which has direct relevance for ETB keepers given how sensitive both C. caninus and C. batesii are to handling and environmental disturbance. Animals with access to a full thermal gradient allowing behavioral thermoregulation may mount a more effective immune response than those kept at a narrow temperature range.

Clinical Signs

Ferlavirus produces three recognizable clinical patterns, and an infected animal may progress through them in sequence or present predominantly with one.

The peracute form involves sudden death with no observable preceding clinical signs. This presentation is more common in vipers but has been reported across snake families, and is part of what makes ferlavirus particularly difficult to manage at the collection level: an animal can appear completely normal and be found dead.

The acute form presents with anorexia, regurgitation, and respiratory signs including open-mouth breathing, gaping, nasal or oral discharge, and audible respiratory sounds. In severe cases, a bloody or brownish discharge may emerge from the glottis, indicating haemorrhagic pneumonia. Neurological signs develop terminally in the acute form and include head tremors, flaccid paralysis, loss of the righting reflex, and convulsions.

The chronic form is characterized by a history of anorexia and regurgitation, progressive weight loss, and general deterioration over a period of months. Diarrhea may develop. Respiratory and neurological signs emerge later in the chronic course as the disease progresses. This form is particularly deceptive because the slow progression can be mistaken for a husbandry problem or a less serious condition until the animal is already significantly compromised.

For ETB keepers, any of the following warrants immediate veterinary evaluation and isolation:

  • Unexplained anorexia lasting more than a few weeks, particularly without a preceding environmental or seasonal explanation

  • Visible oral or nasal discharge

  • Open-mouth breathing or audible respiratory sounds at rest

  • Regurgitation not associated with handling or temperature issues

  • Any neurological sign: head tremors, abnormal posture, inability to right when inverted, loss of muscle tone

  • Sudden unexpected death in a previously healthy animal

Because these signs overlap significantly with those of Nidovirus and Inclusion Body Disease, laboratory testing is required to distinguish between them.

Transmission

Ferlavirus is described as highly contagious. Primary transmission is through respiratory secretions, consistent with the virus's strong tropism for respiratory epithelium. Cloacal shedding has also been documented, indicating fecal-oral transmission is possible. Oral secretions shed during feeding, regurgitation, and normal behavior all represent transmission pathways in a collection setting.

Fomites are a meaningful concern. Shared feeding tools, water dishes, enclosure furniture, and any surfaces contaminated with oral or cloacal material can carry the virus between animals. Because ferlavirus is an enveloped virus, it is less resistant to desiccation and standard disinfectants than non-enveloped pathogens. Standard disinfection protocols using quaternary ammonium compounds, dilute bleach, or other agents effective against enveloped viruses should be adequate on non-porous surfaces. See the Cleaning page for general disinfection protocols.

Snake mites (Ophionyssus natricis) have been implicated as potential mechanical vectors, consistent with their proposed role in transmitting other snake pathogens including reptarenavirus. Mite infestations in a collection where ferlavirus is present or suspected elevate transmission risk and should be addressed immediately. See the Snake Mites page for identification and treatment.

Congenital or vertical transmission has been suggested, and a related reptilian paramyxovirus (Sunshine virus) has confirmed vertical transmission, raising the possibility that ferlavirus-positive adults may transmit to offspring. This is an area where data specific to ferlaviruses remain limited, but it is a reason to treat offspring from any ferlavirus-positive animal with heightened caution and independent testing.

Diagnosis

Several diagnostic approaches are used for ferlavirus, each with different applications and limitations.

RT-PCR targeting the viral L gene is considered the most sensitive and reliable method for detecting active ferlavirus infection. In live animals, oral and cloacal swabs are the practical sample types, with tracheal wash samples offering higher sensitivity for antemortem diagnosis. Oral swabs are the most accessible and are routinely included on reptile respiratory pathogen panels. A broadly reactive PCR targeting the L gene is recommended because it detects all four described genogroups rather than being specific to a single strain. Results should be interpreted alongside clinical signs and history, as a positive PCR confirms the presence of viral RNA but does not by itself indicate the severity of infection or the prognosis. See the Diagnostic Testing page for an overview of available panels.

Serology using the hemagglutination inhibition (HI) assay detects antibodies against ferlavirus and indicates past exposure or current immune response. A positive HI titer does not confirm active disease but is a useful screening tool in collection management, particularly for identifying carrier animals that may be shedding without obvious clinical signs. The HI assay requires a minimum of eight weeks after infection for seroconversion to occur, meaning recently exposed animals may test seronegative. Repeat serological testing four to six months after initial testing is recommended for any animals that had contact with a confirmed positive individual.

At necropsy, histopathology of lung, pancreas, liver, kidney, and brain tissue can confirm characteristic lesions. Intracytoplasmic and intranuclear inclusion bodies have been reported in liver, lung, and pancreas. Immunohistochemistry and in situ hybridization can confirm viral antigen within lesions. For postmortem diagnosis, a pooled organ sample including lung and intestine provides the best detection. Lung and intestine are the tissues with highest viral load and are preferred over other organs for RT-PCR on postmortem material.

Treatment and Supportive Care

There is no specific antiviral treatment for ferlavirus and no vaccine available for any snake disease. Management is entirely supportive, directed at maintaining the animal's condition and addressing secondary complications.

Antibiotic therapy targeting secondary bacterial pneumonia is indicated in most clinically affected animals, given how consistently gram-negative bacteria are found in the respiratory tracts of ferlavirus-affected snakes. Culture and sensitivity testing of oral or respiratory discharge guides antibiotic selection and helps avoid the development of resistant infections with repeated empirical treatment. Nebulization can help loosen respiratory secretions and support airway clearance. Fluid therapy addresses dehydration in animals that have stopped eating or are losing condition rapidly.

Environmental optimization matters. Maintaining correct thermal gradients gives the animal the best chance of mounting an effective immune response. Minimizing stress through reduced handling and disturbance is especially relevant for ETBs, where handling stress is already a management consideration under normal conditions. Ensuring sound ventilation reduces the pathogen burden in the enclosure environment and supports respiratory health.

Infected animals must be isolated immediately from all other collection animals. Dedicated equipment per animal is essential. Any animal that had direct or indirect contact with a confirmed positive individual should be placed in separate isolation and tested, with repeat serological testing recommended at four to six months. The question of euthanasia in severely affected animals should be discussed directly with a veterinarian, particularly where neurological signs are advanced or quality of life is clearly compromised.

All treatment decisions must be made in consultation with a reptile-experienced veterinarian. Drug selection, dosing, and supportive care protocols require professional assessment of the individual animal.

Prevention and Collection Biosecurity

Ferlavirus spreads rapidly within collections once introduced, and prevention is substantially more effective than management after the fact. The core measures are quarantine, testing, and mite control.

All incoming animals should undergo a minimum 90-day quarantine with dedicated equipment and no shared airspace with established collection animals. Oral swab RT-PCR testing should be performed during quarantine as part of a broader respiratory pathogen panel. Serological testing via HI assay adds value as a complementary screen, particularly for identifying animals that have been exposed but may not currently be shedding detectable viral RNA. Because seroconversion requires at least eight weeks, an HI test performed within the first few weeks of quarantine will not capture recent exposure, and repeat testing later in the quarantine period provides better information.

Mite control is part of ferlavirus prevention for the same reasons it is relevant to IBD. Any mite infestation in a collection where ferlavirus is a concern should be treated as an active biosecurity risk and addressed promptly. Maintaining clean, well-managed enclosures with sound cleaning protocols reduces fomite transmission risk between animals.

Animals known to have been exposed to ferlavirus-positive individuals, even if they test negative initially, should be monitored for a minimum of six months with repeat testing before being considered cleared for integration with the established collection.

Relationship to Other Diseases

The respiratory and neurological signs associated with ferlavirus overlap substantially with those of Nidovirus and Inclusion Body Disease. All three should be included in the diagnostic workup of any ETB presenting with respiratory distress, neurological signs, or unexplained decline. Co-infections with other pathogens are possible and have been documented, with concurrent viral and bacterial infections worsening outcomes. The Diseases Overview page provides broader context on pathogens relevant to this genus and guidance on when to pursue testing.